Featured Press Releases

Innovent Biologics announces U.S. FDA IND approval for Phase 3 MarsLight-11 study of IBI363 in squamous NSCLC

Innovent Biologics announces U.S. FDA IND approval for Phase 3 MarsLight-11 study of IBI363 in squamous NSCLC

Jabil acquires Pharmaceutics International, Inc

Jabil acquires Pharmaceutics International, Inc

  • 05 Feb 2025

Jabil Inc. a global leader in engineering, manufacturing, and supply chain solutions, announced...

Persist AI and Nivagen partner to develop AI-driven manufacturing for long-acting injectables

Persist AI and Nivagen partner to develop AI-driven manufacturing for long-acting injectables

Transposon to share Phase 2 results of TPN-101 for C9orf72-related ALS/FTD at ALS ONE Research Symposium.

Transposon to share Phase 2 results of TPN-101 for C9orf72-related ALS/FTD at ALS ONE Research Symposium.

Haleon’s Otrivin® Brand Now Features Aptar’s First Nasal Pump Made with 52% Bio-based Material

Haleon’s Otrivin® Brand Now Features Aptar’s First Nasal Pump Made with 52% Bio-based Material

Cronus Pharma Launches Butorphic® (Butorphanol Tartrate) as a Sterile Injectable Solution

Cronus Pharma Launches Butorphic® (Butorphanol Tartrate) as a Sterile Injectable Solution

FDA Approves New 2-Gram Fibryga® Presentation to Improve Convenience and Precision in Treating Acquired Fibrinogen Deficiency

FDA Approves New 2-Gram Fibryga® Presentation to Improve Convenience and Precision in Treating Acquired Fibrinogen Deficiency

  • Octapharma
  • 08 Jan 2026
Ark Biopharmaceutical Granted China Marketing Authorization for Aizhida in ADHD Treatment

Ark Biopharmaceutical Granted China Marketing Authorization for Aizhida in ADHD Treatment

  • Arkbio
  • 08 Jan 2026
Novotech Appoints Anand Tharmaratnam as Chief Executive Officer

Novotech Appoints Anand Tharmaratnam as Chief Executive Officer

  • Novotech
  • 08 Jan 2026
Coya Therapeutics Announces Results from an Investigator-Initiated Study Showing Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients Treated with Low-Dose IL-2 and CTLA4-Ig

Coya Therapeutics Announces Results from an Investigator-Initiated Study Showing Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients Treated with Low-Dose IL-2 and CTLA4-Ig

  • Coya Therapeutics, Inc.
  • 08 Jan 2026
RoslinCT and BOOST Pharma Form Strategic Manufacturing Partnership to Advance Cell Therapy for Osteogenesis Imperfecta

RoslinCT and BOOST Pharma Form Strategic Manufacturing Partnership to Advance Cell Therapy for Osteogenesis Imperfecta

  • RoslinCT and BOOST Pharma
  • 07 Jan 2026
Orum Therapeutics Names Chad May Chief Scientific Officer to Advance Degrader-Antibody Conjugate Programs

Orum Therapeutics Names Chad May Chief Scientific Officer to Advance Degrader-Antibody Conjugate Programs

  • Orum Therapeutics
  • 05 Jan 2026
Drug Discovery 2024
The Digital Pharma Advances Conference 2026

Most Popular
January   2026
M T W T F S S
      1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31  

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.